Patent ID: 9212227
Filing Date: 2015-12-15
Classification: A61K,A61P,C07K

Abstract:
1. A method of treating a ST2L-mediated inflammatory pulmonary condition, comprising administering a therapeutically effective amount of an isolated antibody antagonist or fragment thereof that specifically binds Domain I (SEQ ID NO: 9) of human ST2L to a patient in need thereof for a time sufficient to treat the ST2L-mediated inflammatory pulmonary condition, wherein the antibody antagonist comprises the heavy chain complementarity determining regions (HCDR1, HCDR2, HCDR3) and the light chain complementarity determining regions (LCDR1, LCDR2, LCDR3) of SEQ ID NOs: 97, 114, 84, 130, 90 and 134, respectively.